JP2009522316A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009522316A5 JP2009522316A5 JP2008548941A JP2008548941A JP2009522316A5 JP 2009522316 A5 JP2009522316 A5 JP 2009522316A5 JP 2008548941 A JP2008548941 A JP 2008548941A JP 2008548941 A JP2008548941 A JP 2008548941A JP 2009522316 A5 JP2009522316 A5 JP 2009522316A5
- Authority
- JP
- Japan
- Prior art keywords
- her2
- egfr
- antibody
- pharmaceutical composition
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 12
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims 9
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims 9
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 claims 9
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 claims 9
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 claims 9
- 206010028980 Neoplasm Diseases 0.000 claims 7
- 201000011510 cancer Diseases 0.000 claims 7
- 241001529936 Murinae Species 0.000 claims 4
- 238000006471 dimerization reaction Methods 0.000 claims 4
- 238000005734 heterodimerization reaction Methods 0.000 claims 4
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 208000026310 Breast neoplasm Diseases 0.000 claims 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 229950008001 matuzumab Drugs 0.000 claims 2
- 201000002528 pancreatic cancer Diseases 0.000 claims 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 2
- 229960000575 trastuzumab Drugs 0.000 claims 2
- 108010006654 Bleomycin Proteins 0.000 claims 1
- 102000004127 Cytokines Human genes 0.000 claims 1
- 108090000695 Cytokines Proteins 0.000 claims 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims 1
- 229930012538 Paclitaxel Natural products 0.000 claims 1
- 108091008605 VEGF receptors Proteins 0.000 claims 1
- 102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 claims 1
- 239000004037 angiogenesis inhibitor Substances 0.000 claims 1
- 229960001561 bleomycin Drugs 0.000 claims 1
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 claims 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims 1
- 229960004316 cisplatin Drugs 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 239000002254 cytotoxic agent Substances 0.000 claims 1
- 231100000599 cytotoxic agent Toxicity 0.000 claims 1
- 229960003668 docetaxel Drugs 0.000 claims 1
- 229960004679 doxorubicin Drugs 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims 1
- 229960005277 gemcitabine Drugs 0.000 claims 1
- 229940127130 immunocytokine Drugs 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 229960004768 irinotecan Drugs 0.000 claims 1
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 claims 1
- 229960001592 paclitaxel Drugs 0.000 claims 1
- -1 small molecule tyrosine kinase inhibitor Chemical class 0.000 claims 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims 1
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 claims 1
- 239000005483 tyrosine kinase inhibitor Substances 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP06000107 | 2006-01-04 | ||
| PCT/EP2006/012133 WO2007076923A1 (en) | 2006-01-04 | 2006-12-15 | Combination therapy using anti-egfr and anti-her2 antibodies |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009522316A JP2009522316A (ja) | 2009-06-11 |
| JP2009522316A5 true JP2009522316A5 (enExample) | 2010-02-12 |
Family
ID=37876938
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008548941A Pending JP2009522316A (ja) | 2006-01-04 | 2006-12-15 | 抗ｅｇｆｒ抗体と抗ｈｅｒ２抗体を用いる併用療法 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US20090214541A1 (enExample) |
| EP (1) | EP1968633B2 (enExample) |
| JP (1) | JP2009522316A (enExample) |
| KR (1) | KR20080110987A (enExample) |
| CN (1) | CN101365486B (enExample) |
| AR (1) | AR059127A1 (enExample) |
| AU (1) | AU2006332212B8 (enExample) |
| BR (1) | BRPI0620888A2 (enExample) |
| CA (1) | CA2636074A1 (enExample) |
| EA (1) | EA015173B1 (enExample) |
| MX (1) | MX2008008564A (enExample) |
| WO (1) | WO2007076923A1 (enExample) |
| ZA (1) | ZA200806723B (enExample) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20100056762A1 (en) | 2001-05-11 | 2010-03-04 | Old Lloyd J | Specific binding proteins and uses thereof |
| PT2163256E (pt) | 2001-05-11 | 2015-11-20 | Ludwig Inst For Cancer Res Ltd | Proteínas de ligação específica e suas utilizações |
| US10118970B2 (en) | 2006-08-30 | 2018-11-06 | Genentech, Inc. | Multispecific antibodies |
| ES2609094T3 (es) | 2007-01-25 | 2017-04-18 | Dana-Farber Cancer Institute, Inc. | Uso de anticuerpos anti-EGFR en el tratamiento de enfermedades mediadas por un EGFR mutante |
| CA2680854C (en) | 2007-03-15 | 2017-02-14 | Ludwig Institute For Cancer Research | Treatment method using egfr antibodies and src inhibitors and related formulations |
| EP2188311B1 (en) | 2007-08-14 | 2016-10-05 | Ludwig Institute for Cancer Research Ltd. | Monoclonal antibody 175 targeting the egf receptor and derivatives and uses thereof |
| NZ586544A (en) * | 2007-12-26 | 2012-07-27 | Vaccinex Inc | Anti-c35 antibody in combination with an ani-her2 antibody in cancer therapies and methods |
| US8193321B2 (en) | 2008-09-03 | 2012-06-05 | Genentech, Inc. | Multispecific antibodies |
| EP2337800B1 (en) | 2008-09-15 | 2013-10-02 | Yeda Research and Development Co. Ltd. | Antibody combinations and use of same for treating cancer |
| US8728479B2 (en) * | 2009-03-31 | 2014-05-20 | The Trustees Of The University Of Pennsylvania | Antigen-binding proteins comprising recombinant protein scaffolds |
| EP3778917A3 (en) * | 2009-12-04 | 2021-06-09 | F. Hoffmann-La Roche AG | Multispecific antibodies, antibody analogs, compositions, and methods |
| US8609095B2 (en) * | 2010-03-04 | 2013-12-17 | Symphogen A/S | Anti-HER2 antibodies and compositions |
| US9155802B2 (en) | 2010-11-01 | 2015-10-13 | Symphogen A/S | Pan-HER antibody composition |
| WO2012156975A1 (en) | 2011-05-16 | 2012-11-22 | Yeda Research And Development Co. Ltd. | COMBINATIONS OF ANTI ErbB ANTIBODIES FOR THE TREATMENT OF CANCER |
| BR112014027291A2 (pt) | 2012-05-02 | 2017-08-08 | Symphogen As | composições de anticorpos pan-her humanizados |
| EP2968556A1 (en) | 2013-03-13 | 2016-01-20 | University Of Kentucky Research Foundation | Methods of administering igg1 antibodies and methods of suppressing angiogenesis |
| WO2014139131A1 (en) * | 2013-03-14 | 2014-09-18 | Crown Bioscience, Inc. | Use of egfr biomarkers for the treatment of gastric cancer with anti-egfr agents |
| US10683353B2 (en) | 2013-07-11 | 2020-06-16 | The Scripps Research Institute | Coiled coil immunoglobulin fusion proteins and compositions thereof |
| JP2016538283A (ja) | 2013-11-13 | 2016-12-08 | ザイムワークス，インコーポレイテッド | Ｅｇｆｒ及び／またはｈｅｒ２を標的にする一価抗原結合性構築物及びその使用 |
| HUE047806T2 (hu) * | 2014-08-29 | 2020-05-28 | Hoffmann La Roche | Kombinációs kezelés tumort célzó IL-2-variáns immuncitokinekkel és humán PD-L1 elleni antitestekkel |
| CN104991065B (zh) * | 2015-07-07 | 2017-01-11 | 复旦大学附属金山医院 | 一种用于诊断乳腺癌的三联标志物及其应用 |
| JP2018062980A (ja) * | 2016-10-12 | 2018-04-19 | 株式会社ジェイテクト | ボールネジ装置、ボールネジ装置の製造方法及びステアリング装置 |
| TW201827077A (zh) * | 2016-12-28 | 2018-08-01 | 美商建南德克公司 | 晚期her2表現癌症之治療 |
| CN117915950A (zh) * | 2021-08-06 | 2024-04-19 | 甘李药业股份有限公司 | 一种多特异性抗体及其用途 |
| CN117430707B (zh) * | 2023-10-25 | 2024-04-19 | 重庆天科雅生物科技有限公司 | 一种cik细胞的制备方法及其在治疗癌症中的用途 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1989006692A1 (en) * | 1988-01-12 | 1989-07-27 | Genentech, Inc. | Method of treating tumor cells by inhibiting growth factor receptor function |
| AU4128089A (en) | 1988-09-15 | 1990-03-22 | Rorer International (Overseas) Inc. | Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic methods employing same |
| KR100240308B1 (ko) | 1991-03-06 | 2000-01-15 | 플레믹 크리스티안 | 인간화된단클론성항체및혼성단클론성항체 |
| CA2103059C (en) * | 1991-06-14 | 2005-03-22 | Paul J. Carter | Method for making humanized antibodies |
| US6410690B1 (en) * | 1995-06-07 | 2002-06-25 | Medarex, Inc. | Therapeutic compounds comprised of anti-Fc receptor antibodies |
| US20030086924A1 (en) | 1999-06-25 | 2003-05-08 | Genentech, Inc. | Treatment with anti-ErbB2 antibodies |
| US7226592B2 (en) | 2002-10-10 | 2007-06-05 | Merck Patent Gmbh | Bispecific anti-Erb-B antibodies and their use in tumor therapy |
| JP2007522157A (ja) * | 2004-02-12 | 2007-08-09 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング | 抗ｅｇｆｒ抗体の高濃縮液体製剤 |
| PE20070207A1 (es) * | 2005-07-22 | 2007-03-09 | Genentech Inc | Tratamiento combinado de los tumores que expresan el her |
-
2006
- 2006-12-15 WO PCT/EP2006/012133 patent/WO2007076923A1/en not_active Ceased
- 2006-12-15 JP JP2008548941A patent/JP2009522316A/ja active Pending
- 2006-12-15 CN CN2006800503998A patent/CN101365486B/zh not_active Expired - Fee Related
- 2006-12-15 MX MX2008008564A patent/MX2008008564A/es not_active Application Discontinuation
- 2006-12-15 KR KR1020087019157A patent/KR20080110987A/ko not_active Withdrawn
- 2006-12-15 AU AU2006332212A patent/AU2006332212B8/en not_active Ceased
- 2006-12-15 CA CA002636074A patent/CA2636074A1/en not_active Abandoned
- 2006-12-15 US US12/086,725 patent/US20090214541A1/en not_active Abandoned
- 2006-12-15 BR BRPI0620888-6A patent/BRPI0620888A2/pt not_active IP Right Cessation
- 2006-12-15 EA EA200870141A patent/EA015173B1/ru not_active IP Right Cessation
- 2006-12-15 EP EP06829664.9A patent/EP1968633B2/en not_active Not-in-force
-
2007
- 2007-01-03 AR ARP070100020A patent/AR059127A1/es unknown
-
2008
- 2008-08-01 ZA ZA200806723A patent/ZA200806723B/xx unknown
-
2014
- 2014-11-10 US US14/536,854 patent/US9522956B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009522316A5 (enExample) | ||
| Tóth et al. | The combination of trastuzumab and pertuzumab administered at approved doses may delay development of trastuzumab resistance by additively enhancing antibody-dependent cell-mediated cytotoxicity | |
| CN106459212B (zh) | 结合erbb-2和erbb-3的抗体 | |
| RU2349340C2 (ru) | Биспецифические антитела к erb-b и их применение для лечения опухолей | |
| AU2013229786B2 (en) | Conditionally active anti-epidermal growth factor receptor antibodies and methods of use thereof | |
| JP2018534933A5 (enExample) | ||
| Fauvel et al. | Antibodies directed against receptor tyrosine kinases: current and future strategies to fight cancer | |
| JP2017149720A5 (enExample) | ||
| RU2011111746A (ru) | Композиции рекомбинантных антител против рецептора эпидермального фактора роста | |
| ME02148B (me) | Notch-vezivni agensi i antagonisti i postupci za njihovo korišćenje | |
| JP2006505545A5 (enExample) | ||
| SI2842573T1 (en) | Monoclonal antibodies against the receptor 2 of the fibroblast growth factor | |
| UA116874C2 (uk) | Імунокон'югат анти-мезотеліну | |
| JP2016166203A5 (enExample) | ||
| AR062840A1 (es) | Terapia tumoral con una combinacion de anticuerpos anti receptor del factor de crecimiento epidermico (her2) | |
| HRP20180104T1 (hr) | Materijal i postupci za liječenje ili prevenciju bolesti povezanih s her-3 | |
| WO2017060322A3 (en) | Ptefb-inhibitor-adc | |
| JP2017512765A5 (enExample) | ||
| HK1202431A1 (en) | Humanized pan-her antibody compositions | |
| CO6270370A2 (es) | Inhibicion de angiogenesis mediante antagonistas o anticuerpos bv8 | |
| Vigna et al. | Targeting the oncogenic Met receptor by antibodies and gene therapy | |
| JP2016094424A5 (enExample) | ||
| Babar et al. | Anti-HER2 cancer therapy and cardiotoxicity | |
| WO2017191327A3 (en) | Her-2 binding antibodies | |
| JP7304815B2 (ja) | Ｅｒｂｂ－２、ｅｒｂｂ－２／ｅｒｂｂ－３陽性腫瘍を有する個体の処置のための、ｅｒｂ－２及びｅｒｂｂ－３の細胞外部分上のエピトープに結合する抗原結合部位を含むｅｒｂｂ－２標的化剤及び二重特異性抗体 |